Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
about
Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumoursNew therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumorsOptimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies.68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETsTemozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.Radionuclide Therapy for Neuroendocrine Tumors.Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy.Radionuclides in oncology clinical practice - review of the literature.The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors.The difference between medicine and magic is that magicians know what they are doingENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
P2860
Q28247667-7CC7C880-D73E-4AFE-9E0D-CC109ADC8825Q30364864-779E45C3-013E-4852-BC8A-CDB9C992EF35Q33435622-F42278F2-DC3C-442F-9D81-7EB325459BC8Q34157391-3B8AAFAA-1C36-4F9B-8024-56B456E375E1Q36107481-A54B52F7-E1F3-416A-BAFE-FD25615C2ED8Q36265194-08E14CBF-4D68-460D-8675-078B26E5D017Q38241463-D5F989D1-061E-4867-8ECA-66EB53E5EC86Q38400485-AAC3CFC5-6145-4B37-9716-D99E8C2B03E3Q38430202-F4FBFF05-BC33-4FF2-BB77-2E53C7891884Q38694105-52044DA3-6B33-40AB-84C8-DD33CB5B9001Q38909078-73E32643-4B70-40DA-9FEE-DE2E864A903FQ39144880-C4AC9F57-9FAA-4F46-A788-77D34B4D7328Q42345704-E1039112-BB4A-4F1D-A6C9-9B3259055AB1Q47128709-A84B198B-256B-4DE4-9F50-A819C459CB66Q47916271-A3FABE9F-1A92-4EBC-B170-2D0425D7D706Q48295398-D02CF840-3D1C-4FA3-A841-4C815D6A5337Q50034009-BFE2FEA9-AE1A-4BC4-A3CC-2256ABC96B54Q50143284-5514462D-A66C-4752-9652-FF61B854D2AAQ53092330-0B6DAD30-7BB0-4671-BC88-9DFF2BA58FDDQ57758762-37CAAD4F-3666-4905-A13D-0F5690E459B1Q57990732-D1F72112-F7D5-4009-AFC4-99C0151159A5
P2860
Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase I-II study of radiopepti ...... w-grade neuroendocrine tumors.
@ast
Phase I-II study of radiopepti ...... w-grade neuroendocrine tumors.
@en
type
label
Phase I-II study of radiopepti ...... w-grade neuroendocrine tumors.
@ast
Phase I-II study of radiopepti ...... w-grade neuroendocrine tumors.
@en
prefLabel
Phase I-II study of radiopepti ...... w-grade neuroendocrine tumors.
@ast
Phase I-II study of radiopepti ...... w-grade neuroendocrine tumors.
@en
P2093
P356
P1476
Phase I-II study of radiopepti ...... w-grade neuroendocrine tumors.
@en
P2093
J Harvey Turner
Phillip G Claringbold
Richard A Price
P304
P356
10.1089/CBR.2012.1276
P577
2012-10-18T00:00:00Z